superoxide dismutase Inhibitors
2 drugsAbout superoxide dismutase
Superoxide dismutases (SODs) are a class of enzymes that catalyze the dismutation of superoxide radicals into oxygen and hydrogen peroxide. They play a crucial role in cellular antioxidant defense, protecting cells from oxidative stress.
While there is currently no genetic evidence directly linking SOD to specific diseases, managing oxidative stress is important in various pathological conditions. This makes SOD a relevant target for drug development, though further research is needed.
Two FDA-approved small molecule drugs, MULTRYS and TRALEMENT, target superoxide dismutase. Both drugs are marketed by AM REGENT for other indications.
Top superoxide dismutase Drugs
AM REGENT is the only company with approved drugs targeting superoxide dismutase.
The market is highly concentrated, indicating potential entry barriers or limited commercial opportunity.
superoxide dismutase Drug Modality Landscape
Modalities
Routes of Administration
superoxide dismutase is druggable by small molecules, though no oral formulations are currently approved.
Explore alternative modalities like biologics to differentiate from existing small molecule SOD modulators.
superoxide dismutase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on superoxide dismutase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
superoxide dismutase Drug Approval Timeline (2020 - 2020)
The first and most recent drug approvals for SOD were in 2020, with MULTRYS and TRALEMENT.
Recent approvals suggest renewed interest, but a short approval span may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on superoxide dismutase. A trial counts if an approved drug acting on superoxide dismutase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.